MET-097i: Sustained GLP-1 Receptor Engagement

σε πρόσθεσε στο άλλο

2025-11-09 12:57:18 -

The development of MET-097i represents a major leap forward in treating metabolic disorders such as obesity and type 2 diabetes. Created by Metsera, this next-generation GLP-1 receptor agonist is engineered as a fully biased, ultra-long-acting peptide designed to extend therapeutic benefits while fine-tuning receptor activity. Unlike conventional GLP-1 drugs, it strategically enhances favorable...

0 Σχόλια 0 Μοιράστηκε 767 Views 0 Προεπισκόπηση